“The present circumstance has uncovered some structural weaknesses while in the EU’s medicines offer chain plus a significant dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides stated. She advisable that offer chain difficulties be resolved in an EU pharmaceutical strategy expected to generally be